(SYNSAM) Synsam AB - Ratings and Ratios

Exchange: ST • Country: Sweden • Currency: SEK • Type: Common Stock • ISIN: SE0016829709

SYNSAM: Glasses, Sunglasses, Sports Glasses, Contact Lenses, Eye Exams

Synsam AB, a publicly traded company, is a leading optical retailer in the Nordic Region, operating a diverse range of stores and ecommerce platforms across Sweden, Denmark, Norway, Iceland, the Faroe Islands, and Finland. The company's product portfolio includes a wide selection of glasses, sunglasses, sports glasses, and contact lenses, catering to various customer needs and preferences. Additionally, Synsam offers glasses and contact lens subscriptions, as well as comprehensive eye examination services, all under the Synsam Lifestyle brand, which emphasizes a holistic approach to eye care and vision correction.

With a history dating back to 1968, Synsam AB has established itself as a trusted and reputable player in the Nordic optical retail market. The company's business model is built around a combination of directly owned and franchised stores, allowing for a strong physical presence in key markets, while also leveraging ecommerce channels to reach a broader customer base. This multi-channel approach enables Synsam to provide convenient and accessible eye care solutions to customers across the region. As a publicly traded company, Synsam AB is committed to transparency and accountability, with its common stock listed under the ISIN code SE0016829709, and classified under the GICS Sub Industry category of Life Sciences Tools & Services.

As a major player in the Nordic optical retail market, Synsam AB is well-positioned to capitalize on growing demand for eye care services and products. The company's website, https://www.synsamgroup.com, provides customers with a user-friendly platform to browse products, book eye examinations, and access information on various eye care services. With its strong brand presence, extensive product range, and commitment to customer satisfaction, Synsam AB is a key player in the Nordic Region's optical retail landscape, with a focus on delivering high-quality eye care solutions to customers across the region.

Additional Sources for SYNSAM Stock

Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle

SYNSAM Stock Overview

Market Cap in USD 604m
Sector Healthcare
Industry Medical Instruments & Supplies
GiC Sub-Industry Life Sciences Tools & Services
IPO / Inception

SYNSAM Stock Ratings

Growth 5y -16.7%
Fundamental 70.3%
Dividend 54.1%
Rel. Strength Industry 243
Analysts -
Fair Price Momentum 45.35 SEK
Fair Price DCF 166.97 SEK

SYNSAM Dividends

Dividend Yield 12m 3.73%
Yield on Cost 5y 3.69%
Annual Growth 5y 1.92%
Payout Consistency 98.8%

SYNSAM Growth Ratios

Growth Correlation 3m -33.8%
Growth Correlation 12m -51.8%
Growth Correlation 5y -37.9%
CAGR 5y -0.28%
CAGR/Mean DD 5y -0.01
Sharpe Ratio 12m 0.35
Alpha -7.86
Beta 0.67
Volatility 32.66%
Current Volume 91.5k
Average Volume 20d 213.5k
What is the price of SYNSAM stocks?
As of January 22, 2025, the stock is trading at SEK 48.30 with a total of 91,530 shares traded.
Over the past week, the price has changed by +6.86%, over one month by +9.28%, over three months by -0.92% and over the past year by +11.50%.
Is Synsam AB a good stock to buy?
Yes, based on ValueRay Fundamental Analyses, Synsam AB (ST:SYNSAM) is currently (January 2025) a good stock to buy. It has a ValueRay Fundamental Rating of 70.26 and therefor a positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of SYNSAM as of January 2025 is 45.35. This means that SYNSAM is currently overvalued and has a potential downside of -6.11%.
Is SYNSAM a buy, sell or hold?
Synsam AB has no consensus analysts rating.
What are the forecast for SYNSAM stock price target?
According to ValueRays Forecast Model, SYNSAM Synsam AB will be worth about 49.5 in January 2026. The stock is currently trading at 48.30. This means that the stock has a potential upside of +2.48%.
Issuer Forecast Upside
Wallstreet Target Price 61.8 27.8%
Analysts Target Price - -
ValueRay Target Price 49.5 2.5%